Publications du centre
Liste des publications
Publications du département d'ophtalmologie
Bienvenue sur la page dédiée aux publications scientifiques du département d'ophtalmologie du centre médical des Aravis. Notre équipe médicale s'investit activement dans la recherche et l'innovation afin d'améliorer constamment la prise en charge de nos patients. Nos travaux portent sur un large éventail de thématiques, notamment :
Domaines d'expertise
- Les maladies de la cornée, telles que le kératocône, et les techniques chirurgicales associées (greffe de cornée, etc.).
- Les pathologies rétiniennes, comme la DMLA ou le décollement de la rétine, avec une expertise particulière dans les traitements par injections intravitréennes et la chirurgie vitréo-rétinienne.
- L'épidémiologie et la santé publique en ophtalmologie, en utilisant des bases de données nationales pour analyser les tendances et les facteurs de risque de différentes maladies oculaires.
- L'impact des technologies numériques sur la santé oculaire, notamment l'utilisation de la télémédecine pour le dépistage de la rétinopathie diabétique.
Nous sommes fiers de partager ici nos contributions à l'avancement des connaissances en ophtalmologie. N'hésitez pas à consulter nos publications pour en savoir plus sur nos domaines d'expertise et nos recherches en cours.
2024
Mathis, Thibaud; Baudin, Florian; Mariet, Anne-Sophie; Augustin, Sébastien; Bricout, Marion; Przegralek, Lauriane; Roubeix, Christophe; Benzenine, Éric; Blot, Guillaume; Nous, Caroline; Kodjikian, Laurent; Mauget-Faÿsse, Martine; Sahel, José-Alain; Plevin, Robin; Zeitz, Christina; Delarasse, Cécile; Guillonneau, Xavier; Creuzot-Garcher, Catherine; Quantin, Catherine; Hunot, Stéphane; Sennlaub, Florian
DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration Article de journal
Dans: J. Clin. Invest., vol. 134, no. 17, 2024.
Résumé | Liens | BibTeX | Étiquettes: Neurodegeneration; Neuroscience; Ophthalmology; Parkinson disease; Retinopathy
@article{Mathis2024-mh,
title = {DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration},
author = {Thibaud Mathis and Florian Baudin and Anne-Sophie Mariet and Sébastien Augustin and Marion Bricout and Lauriane Przegralek and Christophe Roubeix and Éric Benzenine and Guillaume Blot and Caroline Nous and Laurent Kodjikian and Martine Mauget-Faÿsse and José-Alain Sahel and Robin Plevin and Christina Zeitz and Cécile Delarasse and Xavier Guillonneau and Catherine Creuzot-Garcher and Catherine Quantin and Stéphane Hunot and Florian Sennlaub},
url = {https://annecy-ophtalmo.fr/wp-content/uploads/2024/10/jci-134-174199.pdf},
year = {2024},
date = {2024-07-01},
urldate = {2024-07-01},
journal = {J. Clin. Invest.},
volume = {134},
number = {17},
publisher = {American Society for Clinical Investigation},
abstract = {Neovascular age-related macular degeneration (nAMD) remains a
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.},
keywords = {Neurodegeneration; Neuroscience; Ophthalmology; Parkinson disease; Retinopathy},
pubstate = {published},
tppubtype = {article}
}
Neovascular age-related macular degeneration (nAMD) remains a
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.
Mathis, Thibaud; Baudin, Florian; Mariet, Anne-Sophie; Augustin, Sébastien; Bricout, Marion; Przegralek, Lauriane; Roubeix, Christophe; Benzenine, Éric; Blot, Guillaume; Nous, Caroline; Kodjikian, Laurent; Mauget-Faÿsse, Martine; Sahel, José-Alain; Plevin, Robin; Zeitz, Christina; Delarasse, Cécile; Guillonneau, Xavier; Creuzot-Garcher, Catherine; Quantin, Catherine; Hunot, Stéphane; Sennlaub, Florian
DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration Article de journal
Dans: J. Clin. Invest., vol. 134, no. 17, 2024.
Résumé | BibTeX | Étiquettes: Neurodegeneration; Neuroscience; Ophthalmology; Parkinson disease; Retinopathy
@article{Mathis2024-ch,
title = {DRD2 activation inhibits choroidal neovascularization in
patients with Parkinson's disease and age-related macular
degeneration},
author = {Thibaud Mathis and Florian Baudin and Anne-Sophie Mariet and Sébastien Augustin and Marion Bricout and Lauriane Przegralek and Christophe Roubeix and Éric Benzenine and Guillaume Blot and Caroline Nous and Laurent Kodjikian and Martine Mauget-Faÿsse and José-Alain Sahel and Robin Plevin and Christina Zeitz and Cécile Delarasse and Xavier Guillonneau and Catherine Creuzot-Garcher and Catherine Quantin and Stéphane Hunot and Florian Sennlaub},
year = {2024},
date = {2024-07-01},
journal = {J. Clin. Invest.},
volume = {134},
number = {17},
publisher = {American Society for Clinical Investigation},
abstract = {Neovascular age-related macular degeneration (nAMD) remains a
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.},
keywords = {Neurodegeneration; Neuroscience; Ophthalmology; Parkinson disease; Retinopathy},
pubstate = {published},
tppubtype = {article}
}
Neovascular age-related macular degeneration (nAMD) remains a
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.
Explorer
Recherche
1.
Mathis, Thibaud; Baudin, Florian; Mariet, Anne-Sophie; Augustin, Sébastien; Bricout, Marion; Przegralek, Lauriane; Roubeix, Christophe; Benzenine, Éric; Blot, Guillaume; Nous, Caroline; Kodjikian, Laurent; Mauget-Faÿsse, Martine; Sahel, José-Alain; Plevin, Robin; Zeitz, Christina; Delarasse, Cécile; Guillonneau, Xavier; Creuzot-Garcher, Catherine; Quantin, Catherine; Hunot, Stéphane; Sennlaub, Florian
DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration Article de journal
Dans: J. Clin. Invest., vol. 134, no. 17, 2024.
@article{Mathis2024-mh,
title = {DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration},
author = {Thibaud Mathis and Florian Baudin and Anne-Sophie Mariet and Sébastien Augustin and Marion Bricout and Lauriane Przegralek and Christophe Roubeix and Éric Benzenine and Guillaume Blot and Caroline Nous and Laurent Kodjikian and Martine Mauget-Faÿsse and José-Alain Sahel and Robin Plevin and Christina Zeitz and Cécile Delarasse and Xavier Guillonneau and Catherine Creuzot-Garcher and Catherine Quantin and Stéphane Hunot and Florian Sennlaub},
url = {https://annecy-ophtalmo.fr/wp-content/uploads/2024/10/jci-134-174199.pdf},
year = {2024},
date = {2024-07-01},
urldate = {2024-07-01},
journal = {J. Clin. Invest.},
volume = {134},
number = {17},
publisher = {American Society for Clinical Investigation},
abstract = {Neovascular age-related macular degeneration (nAMD) remains a
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Neovascular age-related macular degeneration (nAMD) remains a
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.
2.
Mathis, Thibaud; Baudin, Florian; Mariet, Anne-Sophie; Augustin, Sébastien; Bricout, Marion; Przegralek, Lauriane; Roubeix, Christophe; Benzenine, Éric; Blot, Guillaume; Nous, Caroline; Kodjikian, Laurent; Mauget-Faÿsse, Martine; Sahel, José-Alain; Plevin, Robin; Zeitz, Christina; Delarasse, Cécile; Guillonneau, Xavier; Creuzot-Garcher, Catherine; Quantin, Catherine; Hunot, Stéphane; Sennlaub, Florian
DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration Article de journal
Dans: J. Clin. Invest., vol. 134, no. 17, 2024.
@article{Mathis2024-ch,
title = {DRD2 activation inhibits choroidal neovascularization in
patients with Parkinson's disease and age-related macular
degeneration},
author = {Thibaud Mathis and Florian Baudin and Anne-Sophie Mariet and Sébastien Augustin and Marion Bricout and Lauriane Przegralek and Christophe Roubeix and Éric Benzenine and Guillaume Blot and Caroline Nous and Laurent Kodjikian and Martine Mauget-Faÿsse and José-Alain Sahel and Robin Plevin and Christina Zeitz and Cécile Delarasse and Xavier Guillonneau and Catherine Creuzot-Garcher and Catherine Quantin and Stéphane Hunot and Florian Sennlaub},
year = {2024},
date = {2024-07-01},
journal = {J. Clin. Invest.},
volume = {134},
number = {17},
publisher = {American Society for Clinical Investigation},
abstract = {Neovascular age-related macular degeneration (nAMD) remains a
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Neovascular age-related macular degeneration (nAMD) remains a
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.
major cause of visual impairment and puts considerable burden on
patients and health care systems. l-DOPA-treated Parkinson's
disease (PD) patients have been shown to be partially protected
from nAMD, but the mechanism remains unknown. Using murine
models that combine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
(MPTP-induced) PD and laser-induced nAMD with standard PD
treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific
dopamine receptor inhibitors, we here demonstrate that l-DOPA
treatment-induced increase of dopamine-mediated dopamine
receptor D2 (DRD2) signaling inhibits choroidal
neovascularization independently of MPTP-associated
nigrostriatal pathway lesion. Analyzing a retrospective cohort
of more than 200,000 patients with nAMD receiving anti-VEGF
treatment from the French nationwide insurance database, we show
that DRD2 agonist-treated PD patients have a significantly
delayed age of onset of nAMD and reduced need for anti-VEGF
therapies, similar to the effects of the l-DOPA treatment. While
providing a mechanistic explanation for an intriguing
epidemiological observation, our findings suggest that systemic
DRD2 agonists might constitute an adjuvant therapy to delay and
reduce the need for anti-VEGF therapy in patients with nAMD.